Immunological aspects of ovarian cancer: Therapeutic perspectives

被引:2
|
作者
Nayama, M. [1 ]
Collinet, P. [2 ,4 ]
Salzet, M. [3 ]
Vinatier, D. [2 ,3 ,4 ]
机构
[1] Maternite Issaka Gazoby, Serv Gynecol Obstet, BP 10975, Niamey, Niger
[2] CHU Lille, F-59000 Lille, France
[3] Univ Lille 1, EA 4550, IFR 147, Lab PRISM Proteom Reponse Inflammatoire Spectrome, Batiment SN3,1er Etage, F-59655 Villeneuve Dascq, France
[4] Univ Nord de France, Dept Univ Gynecol Obstet, F-59045 Lille, France
关键词
Ovarian cancer; Immunotherapy; Immune tolerance; REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; HISTONE DEACETYLASE INHIBITORS; PLASMACYTOID DENDRITIC CELLS; CLASS-I EXPRESSION; HLA-G; POOR-PROGNOSIS; ANTAGONIST ANTIBODIES; ANTI-PD-1; ANTIBODY; IMMUNE-RESPONSES;
D O I
10.1016/j.jgyn.2016.05.005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ovarian cancer is recognized by the immunological system of its host. Initially, it is effective to destroy and eliminate the cancer. But gradually, resistant tumor cells more aggressive and those able to protect themselves by inducing immune tolerance will be selected. Immunotherapy to be effective should consider both components of immune response with an action on cytotoxic immune effectors and action on tolerance mechanisms. The manipulations of the immune system should be cautious, because the immune effects are not isolated. A theoretically efficient handling may simultaneously cause an adverse effect which was not envisaged and could neutralize the benefits of treatment. Knowledge of tolerance mechanisms set up by the tumor is for the clinician a prerequisite before they prescribe these treatments. For each cancer, the knowledge of its immunological status is a prerequisite to propose adapted immunological therapies. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1020 / 1036
页数:17
相关论文
共 50 条
  • [21] Immunological aspects of ischaemic stroke - Therapeutic implications
    Stoll, G
    Jander, S
    Siebler, M
    Schroeter, M
    [J]. CNS DRUGS, 2000, 14 (03) : 213 - 228
  • [22] IMMUNOLOGICAL ASPECTS OF CANCER CHEMOTHERAPY
    HASKELL, CM
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1977, 17 : 179 - 195
  • [23] Immunological aspects of cancer chemotherapy
    Zitvogel, Laurence
    Apetoh, Lionel
    Ghiringhelli, Francois
    Kroemer, Guido
    [J]. NATURE REVIEWS IMMUNOLOGY, 2008, 8 (01) : 59 - 73
  • [24] BIOCHEMISTRY OF CANCER - (IMMUNOLOGICAL ASPECTS)
    DAY, ED
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1962, 31 : 549 - +
  • [25] IMMUNOLOGICAL ASPECTS OF COLORECTAL CANCER
    SJOGREN, HO
    [J]. CLINICS IN GASTROENTEROLOGY, 1976, 5 (03): : 563 - 571
  • [26] DISSEMINATED COCCIDIOIDOMYCOSIS - CLINICAL, IMMUNOLOGICAL AND THERAPEUTIC ASPECTS
    DANOFF, D
    MUNK, ZM
    CASE, B
    FINLAYSON, M
    GOLD, P
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 1978, 118 (04) : 390 - 393
  • [27] PACHYONYCHIA-CONGENITA - THERAPEUTIC AND IMMUNOLOGICAL ASPECTS
    ROHOLD, AE
    BRANDRUP, F
    [J]. PEDIATRIC DERMATOLOGY, 1990, 7 (04) : 307 - 309
  • [28] IMMUNOLOGICAL ASPECTS OF CANCER OF BREAST
    MARCUS, DM
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1975, 64 (06) : 786 - 791
  • [29] IMMUNOLOGICAL ASPECTS OF GYNECOLOGIC CANCER
    BARBER, HRK
    DORSETT, B
    [J]. CANCER, 1981, 48 (02) : 472 - 483
  • [30] Immunological aspects of cancer chemotherapy
    Laurence Zitvogel
    Lionel Apetoh
    François Ghiringhelli
    Guido Kroemer
    [J]. Nature Reviews Immunology, 2008, 8 : 59 - 73